ELITE PHARMACEUTICAL
ELI
ELI was delisted on the 20th of May, 2009.
1 hedge funds and large institutions have $4K invested in ELITE PHARMACEUTICAL in 2020 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
60% less capital invested
Capital invested by funds: $9.94K → $4K (-$5.94K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAFL
Jay A. Fishman Ltd
Troy,
Michigan
|
-$5.94K |
| 2 |
HCM
Highlander Capital Management
Short Hills,
New Jersey
|
-$4K |
ELI Hedge Fund Activity: Q2 2020 in Review
1 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q2 2020, worth a combined $4K — down 60% from $9.94K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ELI and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was CAPTRUST Financial Advisors, opening a new position worth an estimated $4K. The largest seller was Jay A. Fishman Ltd, exiting entirely with an estimated $5.94K sold.
- 1 institutional investor held ELITE PHARMACEUTICAL (ELI) as of Q2 2020, down from 2 in Q1 2020.
- Funds reported $4K of ELITE PHARMACEUTICAL stock for Q2 2020, down 60% quarter-over-quarter.
- 1 fund opened new ELITE PHARMACEUTICAL positions in Q2 2020 and 2 closed out, a net change of -1 holder.
- The largest ELITE PHARMACEUTICAL buyer in Q2 2020 was CAPTRUST Financial Advisors, an estimated $4K added.
- The largest ELITE PHARMACEUTICAL seller in Q2 2020 was Jay A. Fishman Ltd, an estimated $5.94K sold.
Based on aggregated 13F filings for Q2 2020.